Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

60 Degrees Pharmaceuticals (SXTP) Gross Margin (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Gross Margin for 4 consecutive years, with 22.87% as the latest value for Q3 2025.

  • On a quarterly basis, Gross Margin fell 4032.0% to 22.87% in Q3 2025 year-over-year; TTM through Sep 2025 was 16.3%, a 30.0% increase, with the full-year FY2024 number at 36.67%, up 12382.0% from a year prior.
  • Gross Margin was 22.87% for Q3 2025 at 60 Degrees Pharmaceuticals, down from 50.41% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 538.03% in Q4 2022 to a low of 325.81% in Q1 2023.
  • A 4-year average of 15.86% and a median of 28.33% in 2024 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: crashed -55441bps in 2023, then skyrocketed 36389bps in 2024.
  • 60 Degrees Pharmaceuticals' Gross Margin stood at 538.03% in 2022, then crashed by -103bps to 16.37% in 2023, then surged by 385bps to 46.67% in 2024, then crashed by -149bps to 22.87% in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Gross Margin are 22.87% (Q3 2025), 50.41% (Q2 2025), and 55.2% (Q1 2025).